Interpace Biosciences Inc Ano de IPO

Qual é o Ano de IPO de Interpace Biosciences Inc?

O Ano de IPO de Interpace Biosciences Inc é 1998

Qual é a definição de Ano de IPO?

A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.

Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.

Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.

The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.

Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com Interpace Biosciences Inc

O que Interpace Biosciences Inc faz?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Empresas com ano de ipo semelhantes a Interpace Biosciences Inc